Cadrenal Therapeutics

CVKDPhase 3

Cadrenal Therapeutics is a publicly traded, late-stage biopharma company focused on developing differentiated anticoagulant therapies for critical unmet needs. Its strategy targets niche, high-mortality conditions like HIT and anticoagulation in end-stage kidney disease patients, where current therapies are inadequate. The company has built a multi-asset pipeline with two Phase 3-ready candidates and has secured key regulatory designations to accelerate development and commercialization.

Market Cap

$15.2M

Focus

Small Molecules

CVKD · Stock Price

USD 6.5255.28 (-89.45%)

Historical price data

AI Company Overview

Technology Platform

Focus on novel pathways in coagulation and thrombosis, including first-in-class 12-lipoxygenase (12-LOX) inhibition for immune-mediated thrombosis and development of next-generation oral Vitamin K Antagonists (VKAs) and Factor XIa inhibitors.

Funding History

Total raised: $7.5M

IPO$6MUndisclosedJan 15, 2023

Seed$1.5MUndisclosedDec 15, 2021

Opportunities

Significant opportunities exist in addressing the high unmet need in HIT with a first-in-class therapy, capturing the large ESKD patient population underserved by current anticoagulants, and penetrating the acute hospital anticoagulation market with a targeted Factor XIa inhibitor.

Orphan drug designations provide potential for accelerated approval and market exclusivity.

Risk Factors

Key risks include clinical trial failure of lead assets, insufficient capital to fund Phase 3 trials, challenges in commercializing niche hospital products, and competition from established therapies and other novel agents in development.

The company's low market capitalization reflects high financial and execution risk.

Competitive Landscape

In HIT, Cadrenal faces competition from IV direct thrombin inhibitors (argatroban/bivalirudin). Its differentiation is targeting the 12-LOX immune pathway. For ESKD, tecarfarin competes with warfarin, aiming for superior dosing predictability. In acute care, frunexian competes with other Factor XIa inhibitors in development, differentiating via its IV formulation for hospital use.